Sudo Bioscience emerged with $37 million in funding and four programs that address TYK2, a promising target for autoimmune diseases. Bristol Myers Squibb drug Sotyktu recently won the first FDA approval for a TYK2 inhibitor but Sudo claims its molecules have the potential to be best in this new drug class.
